A practice change recommending vitamin D supplementation to breast cancer patients receiving paclitaxel chemotherapy reduced nerve damage from 80% to 67% at a rural cancer center, exceeding the 10% reduction goal. According to Gram Research analysis, this quality improvement project found that all patients with low vitamin D levels before treatment developed nerve damage, suggesting vitamin D deficiency may be a key risk factor for this serious chemotherapy side effect.
Cancer patients receiving a chemotherapy drug called paclitaxel often develop painful nerve damage in their hands and feet. Researchers at a rural cancer center tested whether giving vitamin D supplements could reduce this side effect in breast cancer patients. When they started recommending vitamin D to patients, the rate of nerve damage dropped from 80% to 67%, exceeding their goal of a 10% reduction. This small but promising study suggests that checking vitamin D levels and supplementing when needed might be a simple way to protect patients from this serious chemotherapy side effect.
Key Statistics
A quality improvement project at a rural cancer center found that recommending vitamin D supplementation to 27 breast cancer patients receiving paclitaxel reduced chemotherapy-induced peripheral neuropathy from 80% to 67%, a 13% reduction that exceeded the 10% improvement goal.
In the same 2026 study, all 11 patients with vitamin D insufficiency before paclitaxel chemotherapy developed peripheral nerve damage, suggesting low vitamin D may be a significant risk factor for this side effect.
The study compared 20 breast cancer patients treated before vitamin D supplementation was recommended with 27 patients treated after the practice change was implemented between June and December 2024.
The Quick Take
- What they studied: Whether recommending vitamin D supplements to breast cancer patients receiving paclitaxel chemotherapy could reduce nerve damage in their hands and feet.
- Who participated: 47 breast cancer patients at a rural community cancer center: 20 patients before the vitamin D program started and 27 patients after it began.
- Key finding: Nerve damage dropped from 80% of patients before the program to 67% after, a 13% reduction that exceeded the researchers’ 10% goal.
- What it means for you: If you’re receiving paclitaxel chemotherapy, getting your vitamin D levels checked and taking supplements if needed might reduce your risk of developing painful nerve damage. However, this was a small study at one cancer center, so talk with your oncology team before starting any supplements.
The Research Details
This was a quality improvement project, which means the researchers tested a new practice at their cancer center to see if it worked better than their old approach. They compared two groups of breast cancer patients: one group treated before they started recommending vitamin D (January 2022 to December 2023) and another group treated after the new recommendation was in place (June 2024 to December 2024). Both groups received the same chemotherapy drug, paclitaxel, but only the second group was offered vitamin D supplementation.
The researchers tracked how many patients in each group developed chemotherapy-induced peripheral neuropathy, which is the medical term for nerve damage that causes pain, numbness, or tingling in the hands and feet. They also looked at which patients had low vitamin D levels before treatment started.
This type of study is valuable because it tests whether a simple, low-cost change in how doctors treat patients can prevent a serious side effect. Unlike laboratory studies, this approach looks at real patients in a real cancer center, making the results more directly applicable to clinical practice. The researchers were also careful to compare similar groups of patients before and after the change.
This study has some important limitations to consider. It was small, with only 47 patients total, and took place at just one rural cancer center, so results may not apply everywhere. The study didn’t randomly assign patients to receive vitamin D or not, which is the gold standard for proving cause and effect. However, the study did meet its stated goal and provides early evidence that vitamin D supplementation might help.
What the Results Show
The main finding was that nerve damage from paclitaxel chemotherapy decreased significantly after the cancer center started recommending vitamin D supplements. Before the program, 80% of patients (16 out of 20) developed nerve damage. After the program started, only 67% of patients (18 out of 27) developed nerve damage. This 13% reduction exceeded the researchers’ goal of at least a 10% improvement.
Another striking finding emerged when the researchers looked at patients with low vitamin D levels. Every single patient who had insufficient vitamin D before treatment started went on to develop nerve damage. This suggests that vitamin D deficiency might be an important risk factor for this chemotherapy side effect.
The study did not report detailed information about how severe the nerve damage was in each group or whether vitamin D supplementation affected other chemotherapy side effects. The researchers also did not provide information about how much vitamin D was recommended or how well patients took the supplements.
According to Gram Research analysis, previous studies have shown that chemotherapy-induced peripheral neuropathy affects 30% to 90% of patients receiving paclitaxel, depending on the dose and treatment duration. Several earlier studies found connections between low vitamin D levels and increased nerve damage risk, but few cancer centers had tested whether actually giving vitamin D supplements could prevent this problem. This study is among the first to test this simple intervention in a real-world cancer treatment setting.
The study was small, with only 47 patients total, which means the results might not apply to larger or more diverse groups. The study took place at one rural cancer center, so results may differ at other hospitals or in urban areas. The researchers did not randomly assign patients to receive vitamin D or not, which makes it harder to prove that vitamin D was the reason for the improvement. Some patients may have had other differences between the two time periods that could have affected results. The study also did not track how long patients took vitamin D supplements or whether they took them as recommended.
The Bottom Line
Based on this early evidence, oncology teams may want to consider checking vitamin D levels in breast cancer patients before they start paclitaxel chemotherapy and recommending supplements if levels are low. However, this recommendation is based on a small study at one cancer center, so more research is needed. Patients should discuss vitamin D supplementation with their oncology team rather than starting it on their own, since high doses can be harmful.
This research is most relevant to breast cancer patients about to receive paclitaxel chemotherapy, their oncologists, and cancer center administrators. It may also be relevant to patients receiving other chemotherapy drugs that cause nerve damage. People with other types of cancer or those not receiving chemotherapy should not assume these findings apply to them without talking to their doctor.
Nerve damage from chemotherapy typically develops during or shortly after treatment. If vitamin D supplementation helps prevent this problem, patients would likely see benefits during the weeks and months of chemotherapy. However, some nerve damage can develop months or even years after treatment ends, so longer follow-up would be needed to know if vitamin D provides lasting protection.
Frequently Asked Questions
Can vitamin D prevent nerve damage from chemotherapy?
A 2026 quality improvement study found that recommending vitamin D supplements reduced nerve damage from paclitaxel chemotherapy from 80% to 67% in breast cancer patients. However, this was a small study at one cancer center, so more research is needed before making this a standard recommendation.
What is chemotherapy-induced peripheral neuropathy and why does it happen?
Chemotherapy-induced peripheral neuropathy is nerve damage that causes numbness, tingling, or pain in the hands and feet. It happens because some chemotherapy drugs, including paclitaxel, can damage the nerves that carry signals between your body and brain. The exact reason vitamin D might help prevent this is not yet fully understood.
Should I take vitamin D supplements if I’m getting paclitaxel chemotherapy?
Talk with your oncology team before starting any supplements, including vitamin D. They can check your vitamin D levels and recommend the right dose for you. Taking too much vitamin D can be harmful, so it’s important to get professional guidance rather than self-treating.
How much vitamin D do cancer patients need?
The study did not specify the exact vitamin D doses recommended. Normal vitamin D recommendations are 600 to 800 IU daily for most adults, but cancer patients may need different amounts. Your oncology team can order a blood test to check your vitamin D level and recommend an appropriate dose.
Does this vitamin D finding apply to other types of cancer or chemotherapy drugs?
This study only looked at breast cancer patients receiving paclitaxel. Other cancers and chemotherapy drugs may have different relationships with vitamin D. Always ask your oncology team whether findings from one study apply to your specific situation.
Want to Apply This Research?
- Track your vitamin D supplement dose and timing daily, and record any new numbness, tingling, or pain in your hands or feet weekly using a 0-10 scale. This helps you and your oncology team spot nerve damage early and adjust treatment if needed.
- If your oncology team recommends vitamin D supplementation, set a daily phone reminder to take it at the same time each day, such as with breakfast. Store your supplements in a visible place to help you remember. Keep a simple checklist of doses taken each week to share with your cancer care team.
- Throughout your chemotherapy treatment, use the app to log any new or worsening tingling, numbness, or pain in your hands or feet. Also track your vitamin D supplement adherence. Share these logs with your oncology team at each visit so they can monitor for nerve damage and adjust your care plan if needed.
This article summarizes research findings and is not medical advice. Chemotherapy-induced peripheral neuropathy is a serious side effect that requires professional medical management. Do not start, stop, or change any supplements or medications without consulting your oncology team. Vitamin D supplementation may interact with other medications or conditions. This study was small and conducted at one cancer center, so results may not apply to all patients. Always discuss any new treatments or supplements with your healthcare provider before beginning them.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.